Figure 3.
Targeting for inhibition the TpoR in MPNs. Sites of inhibition for TpoR could be the extracellular juxtamembrane region, the cytosolic juxtamembrane domain containing the W515 residue, and the cytosolic phosphorylated Y626, which is absolutely required for in vivo pathogenic effects of TpoR W515 mutants.